Počet záznamů: 1
alpha-Tocopheryloxyacetic acid is superior to alpha-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability
- 1.
SYSNO ASEP 0383035 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název alpha-Tocopheryloxyacetic acid is superior to alpha-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability Tvůrce(i) Dong, L. F. (AU)
Grant, G. (AU)
Massa, H. (AU)
Zobalová, Renata (BTO-N) RID
Akporiaye, E. (US)
Neužil, Jiří (BTO-N) RIDZdroj.dok. International Journal of Cancer. - : Wiley - ISSN 0020-7136
Roč. 131, č. 5 (2012), s. 1052-1058Poč.str. 7 s. Jazyk dok. eng - angličtina Země vyd. DE - Německo Klíč. slova Breast cancer ; vitamin E analogs ; apoptosis induction Vědní obor RIV CE - Biochemie CEP GAP301/10/1937 GA ČR - Grantová agentura ČR KAN200520703 GA AV ČR - Akademie věd CEZ AV0Z50520701 - BTO-N (2007-2013) UT WOS 000305756900032 DOI 10.1002/ijc.26489 Anotace Breast cancer is the number one neoplastic disease of women, with the HER2-high carcinomas presenting a considerable challenge for efficient treatment. Therefore, a search for novel agents active against this type of cancer is warranted. We tested two vitamin E (VE) analogs, the esterase-hydrolyzable a-tocopheryl succinate (a-TOS) and the non-hydrolyzable ether a-tocopheryloxyacetic acid (a-TEA) for their effects on HER2-positive breast carcinomas using a breast tumor mouse model and breast cancer cell lines. Ultrasound imaging documented that a-TEA suppressed breast carcinomas in the transgenic animals more efficiently than found for its ester counterpart. However, both agents exerted a comparable apoptotic effect on the NeuTL breast cancer cells derived from the FVB/N c-neu mice as well as in the human MBA-MD-453 and MCF7HER2-18 cells with high level of HER2. The superior anti-tumor effect of a-TEA over a-TOS in vivo can be explained by longer persistence of the former in mice, possibly due to the enhanced plasma and hepatic processing of a-TOS in comparison to the esterase-non-cleavable a-TEA. Indeed, the stability of a-TOS in plasma was inferior to that of a-TEA. We propose that a-TEA is a promising drug efficient against breast cancer, as documented by its effect on experimental HER2-positive breast carcinomas that present a considerable problem in cancer management. Pracoviště Biotechnologický ústav Kontakt Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Rok sběru 2013
Počet záznamů: 1